[{"Assets_0_Q3_USD":929079000.0,"CommonStockSharesOutstanding_0_Q3_shares":58167932.0,"NetCashProvidedByUsedInOperatingActivities_3_Q3_USD":-230234000.0,"NetIncomeLoss_1_Q3_USD":-94664000.0,"NetIncomeLoss_3_Q3_USD":-254234000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q3_USD":15198000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_3_Q3_USD":64374000.0,"StockholdersEquity_0_Q3_USD":760213000.0,"Ticker":"AGIO","CIK":"1439222","name":"AGIOS PHARMACEUTICALS INC","OfficialName":"Agios Pharmaceuticals Inc. Common Stock","form":"10-Q","period":"20180930","fy":"2018.0","fp":"Q3","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"1422760526.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20181101"}]